Issue |
J Oral Med Oral Surg
Volume 24, Number 4, December 2018
|
|
---|---|---|
Page(s) | 178 - 181 | |
Section | Cas clinique et revue de la littérature / Up-to date review and case report | |
DOI | https://doi.org/10.1051/mbcb/2018018 | |
Published online | 17 December 2018 |
Up-to Date Review And Case Report
Injection of ropivacaine combined with pregabalin in a patient with post-traumatic trigeminal neuropathic pain
Odontology and Oral Health Division, Functional Unit of Oral Surgery, Bordeaux- University of Bordeaux, Bordeaux, France
* Correspondence: sophie.tisne@free.fr
Received:
3
April
2018
Accepted:
18
June
2018
Introduction: Post-traumatic painful trigeminal neuropathy is a chronic facial pain secondary to trigeminal nerve injury. The treatment of this pain is a therapeutic issue due to the alteration of quality of life that it generates. Observation: A 58-year-old man whose main history of facial trauma has been consulted in the Odontology Department for bilateral trigeminal neuropathic pain that has been evolving for several months. The interrogation revealed continuous pain like electric shocks in the canine areas and daily painful exacerbations. Hyperesthesia and allodynia were found on clinical examination. The patient had received several treatments, oral and local, without significant improvement. As a last resort, injections of ropivacaine every 2 weeks associated with pregabalin (200 mg/day) were performed. At 6 months, there was a clear decrease in the burning sensation and a complete disappearance of painful exacerbations. Discussion: Two studies have recently shown the benefit of the combination of an antiepileptic and a local analgesic in the treatment of classical trigeminal neuralgia, justifying their use in a context of post-traumatic neuropathic pain. Conclusion: Further studies with higher levels of evidence are needed to confirm these preliminary results.
Key words: ropivacaine / pregabalin / trigeminal neuropathy
© The authors, 2018
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.